Loading your page…
The Journal of International Advanced Otology
By Begüm Yılmaz, Ayşe Asli Şahin Yılmaz, Kadri İla and 3 others.
Exenatide, a glucagon-like peptide-1 receptor agonist, has been shown to promote functional recovery and nerve regeneration after nerve crush injury. The aim of this study was to investigate the effect of exenatide on facial nerve regeneration in traumatic facial paralysis.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
This prospective, randomized animal study included 28 healthy female Sprague–Dawley rats divided into 4 groups of 7 rats each: control group, sham group, 2.5 μg/rat/day exenatide-treated group, and 10 μg/rat/day exenatide-treated group. Exenatide was injected subcutaneously for 14 days. Crush injury was applied to the left facial nerve in all groups except the sham group. Functional assessment, electrophysiological, histopathological, and immunohistochemical examinations were performed after crush injury.
The blink reflex score was higher in 10 μg exenatide-treated rats than in other rats at week 1. At weeks 3 and 4, the vibrissae movement score was higher in exenatide-treated rats than in untreated rats. Electromyographic assessments performed at weeks 2 and 4 showed higher amplitude values and shorter latency periods in the exenatide treatment groups. Exenatide was found to have a dose-dependent effect on reducing the severity of vasoconstriction, and this effect was statistically significant. When comparing the exenatide treatment groups with the control group, a significant reduction in the incidence of severe macrovacuolation and an increase in myelin thickness were observed (P < .05).
Functional, electrophysiological, and histopathological evaluations have shown that exenatide treatment has a positive and accelerating effect on facial nerve recovery in traumatic facial paralysis.
Published in The Journal of International Advanced Otology. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
